This is a repository copy of Transforming growth factor-beta globally and specifically inhibits natural killer cells.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/85247/

Version: Accepted Version

Proceedings Paper:

https://doi.org/10.1111/imm.12405

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Erica B Wilson, Josephine L Meade, Adam C Davison, Alastair P Droop and Graham P Cook

Institute of Cancer and Pathology, University of Leeds School of Medicine.

Transforming growth factor-β globally and specifically inhibits Natural killer cells

Human natural killer (NK) cells are important in the innate immune response against viral infection and tumours. In the human tumour microenvironment resident and infiltrating lymphocytes are subjected to a multiple soluble factors that determine their activation status and cell fate. One such factor is Transforming Growth Factor (TGF)-beta a pleiotropic cytokine secreted by tumours but also by multiple cell types such as tumour associated stroma and immune cells such as macrophages.

We have previously shown that TGF-β can counteract NK cell activation, reducing the expression of multiple NK cell activation receptors and effector molecules, such as the cytotoxic apparatus and interferon-gamma. However the extent of this inhibition had not been examined.

Using gene expression profiling and a method for high-throughput multiplex flow cytometry, we have analysed the effect of cytokines and tumour cells on the human NK cell surface phenotype. Our results show that the composition of the NK cell surface is highly dynamic, with numerous cell surface molecules being co-ordinately regulated by activation and inhibition events and we identify a number of novel molecules associated with an inhibited NK cell phenotype. Furthermore, gene expression profiling has identified pathways by which NK cell activation and inhibition might be modulated. Such pathways represent potential targets for agents that might modify NK cell activation to improve the immunosurveillance function of these cells.